CO2018011457A2 - Composiciones de inmunoglobulina intravenosa recombinante (rivig) y métodos para su producción y uso - Google Patents
Composiciones de inmunoglobulina intravenosa recombinante (rivig) y métodos para su producción y usoInfo
- Publication number
- CO2018011457A2 CO2018011457A2 CONC2018/0011457A CO2018011457A CO2018011457A2 CO 2018011457 A2 CO2018011457 A2 CO 2018011457A2 CO 2018011457 A CO2018011457 A CO 2018011457A CO 2018011457 A2 CO2018011457 A2 CO 2018011457A2
- Authority
- CO
- Colombia
- Prior art keywords
- rivig
- immune
- proteins
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 2
- 102000018358 immunoglobulin Human genes 0.000 title abstract 2
- 238000001990 intravenous administration Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 208000026278 immune system disease Diseases 0.000 abstract 3
- 241000282465 Canis Species 0.000 abstract 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 abstract 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 abstract 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 abstract 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000023328 Basedow disease Diseases 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 abstract 1
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 208000015023 Graves' disease Diseases 0.000 abstract 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 abstract 1
- 208000011200 Kawasaki disease Diseases 0.000 abstract 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 abstract 1
- 238000010322 bone marrow transplantation Methods 0.000 abstract 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 abstract 1
- 201000001981 dermatomyositis Diseases 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Composiciones de proteínas de inmunoglobulina intravenosa recombinante (rIVIG) y métodos para la purificación y el uso de las proteínas rIVIG. Las composiciones comprenden moléculas Fc oligoméricas que se unen a los receptores de Fc con avidez elevada. Las proteínas rIVIG son útiles como moléculas inmunomoduladoras para el tratamiento de trastornos inmunitarios, inclusive enfermedades autoinmunes, tales como trombocitopenia inmune refractaria, polineuropatía desmielinizante inflamatoria crónica, esclerosis múltiple, lupus, enfermedad de Graves, enfermedad de Kawasaki, dermatomiositis, miastenia gravis, síndrome de Guillain-Barre, anemia hemolítica autoinmune y otras afecciones inmunitarias e inflamatorias. Las proteínas rIVIG también se pueden utilizar como inmunomoduladores en pacientes para reducir el rechazo inmunitario de trasplantes de órganos, trasplantes de células madre y trasplante de médula ósea. Adicionalmente, la presente invención proporciona proteínas rIVIG de origen no humano, para su uso en trastornos inmunitarios veterinarios, tales como proteínas rIVIG caninas para el tratamiento de perros que padecen de anemia hemolítica autoinmune, púrpura trombocitopénica inmune, artritis reumatoide u otro trastorno inmunitario canino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315483P | 2016-03-30 | 2016-03-30 | |
| PCT/US2017/024650 WO2017172853A1 (en) | 2016-03-30 | 2017-03-29 | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018011457A2 true CO2018011457A2 (es) | 2019-02-08 |
Family
ID=59965144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0011457A CO2018011457A2 (es) | 2016-03-30 | 2018-10-26 | Composiciones de inmunoglobulina intravenosa recombinante (rivig) y métodos para su producción y uso |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11304994B2 (es) |
| EP (1) | EP3436484A4 (es) |
| JP (1) | JP7075100B2 (es) |
| KR (1) | KR102477536B1 (es) |
| CN (1) | CN109312000A (es) |
| AU (1) | AU2017245143B2 (es) |
| BR (1) | BR112018070022A2 (es) |
| CA (1) | CA3019530A1 (es) |
| CL (1) | CL2018002769A1 (es) |
| CO (1) | CO2018011457A2 (es) |
| EA (1) | EA201891999A1 (es) |
| IL (1) | IL261968A (es) |
| MA (1) | MA44517A (es) |
| MX (1) | MX2018011865A (es) |
| SG (1) | SG11201808541VA (es) |
| TW (1) | TWI801336B (es) |
| WO (1) | WO2017172853A1 (es) |
| ZA (1) | ZA201806767B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3723791T3 (da) | 2017-12-14 | 2024-04-08 | CSL Behring Lengnau AG | Rekombinante igg-fc-multimere til behandling af neuromyelitis optica |
| EP3863673A4 (en) * | 2018-10-11 | 2023-01-11 | Momenta Pharmaceuticals, Inc. | TREATMENT WITH HIGHLY SIALYLATED IGG COMPOSITIONS |
| JP2022504868A (ja) * | 2018-10-18 | 2022-01-13 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体 |
| CN109793894A (zh) * | 2019-04-03 | 2019-05-24 | 长春西诺生物科技有限公司 | 犬免疫球蛋白在制备犬溶血性贫血药物中的应用 |
| US20220332847A1 (en) | 2019-09-13 | 2022-10-20 | CSL Behring Lengnau AG | RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS |
| CN112899301B (zh) * | 2021-01-29 | 2023-04-11 | 中国热带农业科学院热带生物技术研究所 | 一种木薯普通花叶病毒诱导的基因沉默系统及其应用 |
| CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106846C (zh) * | 1997-08-21 | 2003-04-30 | 宝酒造株式会社 | 抗癌症剂 |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| GB0015426D0 (en) * | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| EP1395605B8 (en) | 2001-03-09 | 2014-12-17 | Iterative Therapeutics, Inc. | Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors |
| US7279329B2 (en) * | 2005-10-17 | 2007-10-09 | Industrial Technology Research Institute | Expression system for producing collagen |
| US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| CN101802197A (zh) * | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法 |
| CN101835802B (zh) | 2007-06-01 | 2014-04-09 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| WO2010065578A2 (en) | 2008-12-04 | 2010-06-10 | Leukosight Inc. | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME |
| AU2011282579B2 (en) | 2010-07-28 | 2014-10-23 | Gliknik Inc. | Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions |
| EP2561888A1 (en) | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| JP6373836B2 (ja) | 2012-07-26 | 2018-08-15 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | 多量体融合タンパク質ワクチン及び免疫療法 |
| US9683044B2 (en) | 2012-08-20 | 2017-06-20 | Gliknik Inc. | Molecules with antigen binding and polyvalent FC gamma receptor binding activity |
| RU2015118063A (ru) * | 2012-10-17 | 2016-12-10 | Ливерпуль Скул Оф Тропикал Медисин | Иммуномодулирующие белки |
| JP6561042B2 (ja) | 2013-03-13 | 2019-08-14 | ジェンザイム・コーポレーション | Ｐｄｇｆおよびｖｅｇｆ結合部分を含む融合タンパク質ならびにその使用方法 |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| BR112016023948A2 (pt) | 2014-04-16 | 2018-01-30 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| EP3763378A1 (en) | 2015-08-06 | 2021-01-13 | President and Fellows of Harvard College | Improved microbe-binding molecules and uses thereof |
-
2017
- 2017-03-29 BR BR112018070022A patent/BR112018070022A2/pt unknown
- 2017-03-29 KR KR1020187030960A patent/KR102477536B1/ko active IP Right Grant
- 2017-03-29 AU AU2017245143A patent/AU2017245143B2/en active Active
- 2017-03-29 EA EA201891999A patent/EA201891999A1/ru unknown
- 2017-03-29 CN CN201780033114.8A patent/CN109312000A/zh active Pending
- 2017-03-29 US US16/089,042 patent/US11304994B2/en active Active
- 2017-03-29 MX MX2018011865A patent/MX2018011865A/es unknown
- 2017-03-29 WO PCT/US2017/024650 patent/WO2017172853A1/en active Application Filing
- 2017-03-29 CA CA3019530A patent/CA3019530A1/en active Pending
- 2017-03-29 MA MA044517A patent/MA44517A/fr unknown
- 2017-03-29 EP EP17776516.1A patent/EP3436484A4/en active Pending
- 2017-03-29 SG SG11201808541VA patent/SG11201808541VA/en unknown
- 2017-03-29 JP JP2019503393A patent/JP7075100B2/ja active Active
- 2017-03-30 TW TW106110897A patent/TWI801336B/zh active
-
2018
- 2018-09-26 IL IL261968A patent/IL261968A/en unknown
- 2018-09-28 CL CL2018002769A patent/CL2018002769A1/es unknown
- 2018-10-11 ZA ZA2018/06767A patent/ZA201806767B/en unknown
- 2018-10-26 CO CONC2018/0011457A patent/CO2018011457A2/es unknown
-
2022
- 2022-03-29 US US17/707,243 patent/US11801286B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3436484A1 (en) | 2019-02-06 |
| TW201741335A (zh) | 2017-12-01 |
| US20190111115A1 (en) | 2019-04-18 |
| EA201891999A1 (ru) | 2019-08-30 |
| ZA201806767B (en) | 2023-04-26 |
| CN109312000A (zh) | 2019-02-05 |
| KR102477536B1 (ko) | 2022-12-13 |
| KR20180132731A (ko) | 2018-12-12 |
| CL2018002769A1 (es) | 2018-12-28 |
| WO2017172853A1 (en) | 2017-10-05 |
| AU2017245143B2 (en) | 2024-01-11 |
| MX2018011865A (es) | 2019-03-28 |
| AU2017245143A1 (en) | 2018-10-18 |
| US20220233658A1 (en) | 2022-07-28 |
| BR112018070022A2 (pt) | 2019-02-05 |
| TWI801336B (zh) | 2023-05-11 |
| SG11201808541VA (en) | 2018-10-30 |
| EP3436484A4 (en) | 2019-12-04 |
| JP2019513024A (ja) | 2019-05-23 |
| US11801286B2 (en) | 2023-10-31 |
| IL261968A (en) | 2018-10-31 |
| MA44517A (fr) | 2019-02-06 |
| JP7075100B2 (ja) | 2022-05-25 |
| CA3019530A1 (en) | 2017-10-05 |
| US11304994B2 (en) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018011457A2 (es) | Composiciones de inmunoglobulina intravenosa recombinante (rivig) y métodos para su producción y uso | |
| CO2018004090A2 (es) | Anticuerpos anti-tigit y métodos de uso | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| EA201691266A1 (ru) | Анти-cd3 антитела и способы применения | |
| PH12016501391A1 (en) | High affinity and aggregatively stable antibodies on the basis of vairable domain vl and a derivative vhh | |
| EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
| CL2016003335A1 (es) | Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos | |
| EA201690803A1 (ru) | Получение переориентирующих т-клетки гетеродимерных иммуноглобулинов | |
| EA201791422A1 (ru) | Фармацевтические продукты и устойчивые жидкие композиции антител к il-17 | |
| EA202190808A2 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| CL2016001579A1 (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos. | |
| CL2016001968A1 (es) | Proteinas de fusion de interleucina-2 y usos de las mismas | |
| EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| EA201791590A1 (ru) | Антитела к tau и их применение | |
| BR112016012149A2 (pt) | Composição para materiais ópticos, métodos para produzir um material óptico e uma composição para materiais ópticos, material óptico, e, lente óptica | |
| PE20190371A1 (es) | Anticuerpos de interferon beta y usos de los mismos | |
| EA201691521A1 (ru) | Антитела к интерлейкину-21 | |
| ZA201904097B (en) | Anti-il-5 antibodies | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA201990998A1 (ru) | Фармацевтические составы и способы их получения | |
| MX2016002188A (es) | Composición farmacéutica de proteínas híbridas recombinantes capaces de generar anticuerpos neutralizantes en contra del veneno de alacranes. | |
| EA201892257A1 (ru) | Анти-cd3 антитела и способы применения | |
| NZ763852A (en) | Improved immunoglobulin variable domains | |
| Shea | Master's Recital |